TheEdgeResearch
Home / Stocks / GPFT

Grapefruit USA, Inc. (GPFT)

OTC Healthcare Drug Manufacturers - Specialty & Generic
$0.00 ▼ -50.00%
Market Cap
$71,740
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Beta
-0.03
52-Wk Range
0.0001-0.0016
CEO
Bradley J. Yourist
Country
US
Currency
USD

Grapefruit USA, Inc. operates in the Drug Manufacturers - Specialty & Generic industry of the Healthcare sector, headquartered in Los Angeles, CA, US. The stock last traded at $0.00, down 50.00% on the session, giving a market capitalisation of $71,740. On trailing twelve-month figures it carries a trailing P/E of -0.33, a net margin of 0.0%. Its beta of -0.03 implies it has historically moved less than the broad market.

Valuation & profitability (TTM)
P/E
-0.33
Price / Sales
0.00
Price / Book
-0.01
EV / EBITDA
-22.39
Gross margin
0.0%
Operating margin
0.0%
Net margin
0.0%
Return on equity
Debt / equity
-0.61
Current ratio
0.00
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
Other OTC
Employees
9
IPO date
2016-06-23
Headquarters
Los Angeles, CA, US
About Grapefruit USA, Inc.

Grapefruit USA, Inc. is a company dedicated to the creation and distribution of cannabis-related goods, primarily serving the California market. A key offering from the firm is Hourglass, a topical cream featuring a sustained-release blend of THC and CBD, which is exclusively sold via its online platform. The business, originally established in 2017, was formerly recognized as Grapefruit Boulevard Investments, Inc., before officially adopting its current name, Grapefruit USA, Inc., in January 2020. Its main operational base is situated in Wilmington, Delaware.

Comparable companies

Grapefruit USA, Inc. is most often compared with the following Healthcare names:

CBDLFFNTFHPMMIVIXFJUVAFLRSVRLBDSFLMSHWZVDRM
More research on GPFT
GPFT technical analysis GPFT TheEdge Score Compare against peers
Open full interactive analysis & DCF →